Epilepsy is one of the most common neurological chronic disorders, with an estimated
prevalence of 0. 5–1%. Currently, treatment options for epilepsy are predominantly based on …

Epilepsy is one of the most common and disabling chronic neurological disorders.
Antiseizure medications (ASMs), previously referred to as anticonvulsant or antiepileptic …

Reactive astrocytes play an important role in neurological diseases, but their molecular and
functional phenotypes in epilepsy are unclear. Here, we show that in patients with temporal …

Epilepsy affects~ 65 million people worldwide. First-line treatment options include> 20
antiseizure medications, but seizure control is not achieved in approximately one-third of …

Objective This study was undertaken to develop consensus‐based recommendations for the
management of adult and pediatric patients with new onset refractory status epilepticus …

Neuroinflammation is one of the host defensive mechanisms through which the nervous
system protects itself from pathogenic and or infectious insults. Moreover, neuroinflammation …

Reprogramming brain-resident glial cells into clinically relevant induced neurons (iNs) is an
emerging strategy toward replacing lost neurons and restoring lost brain functions. A …

Epilepsy is a complex neurological syndrome characterized by seizures resulting from
neuronal hyperexcitability and sudden and synchronized bursts of electrical discharges …

Rationally designed multi-target drugs (also termed multimodal drugs, network therapeutics,
or designed multiple ligands) have emerged as an attractive drug discovery paradigm in the …

Drug resistance is estimated to affect about a third of individuals with epilepsy, but its
prevalence differs in relation to the epilepsy syndrome, the cause of epilepsy, and other …